Tag Archives: ARR

Linux

How to escape the tabspaces while sending email?

Leave a comment

By Ariean

Hello All,

I have below excerpt from a shell script(bash) and the output from it as shown below. How do i make the email come out with message body left justified. As of now because of those tabs the message is coming out with those tab spaces. May i please know how can i supress them?

Code:
if [ $( echo "${TOT_PRINCIPAL_BALANCE_DOLLARS} == ${COMP_PRINCIPAL_BALANCE_DOLLARS}" | bc -l ) -eq 1 ]
then
logit "Principal Balance Dollars For Uninum($UNINUM): ${TOT_PRINCIPAL_BALANCE_DOLLARS} Matches With ${COMP_PRINCIPAL_BALANCE_DOLLARS}"
else
logit "Principal Balance Dollars For Uninum($UNINUM): ${TOT_PRINCIPAL_BALANCE_DOLLARS} Doesn't Match With ${COMP_PRINCIPAL_BALANCE_DOLLARS}"
((i+=1))
#ARR[$i]="Principal Balance Dollars For Uninum($UNINUM): '${TOT_PRINCIPAL_BALANCE_DOLLARS}' Doesn't Match With '${COMP_PRINCIPAL_BALANCE_DOLLARS}'"
ARR[$i]="
Uninum: $UNINUM
Provider: $PROVIDER
Principal Balance Dollars: '${TOT_PRINCIPAL_BALANCE_DOLLARS}' Doesn't Match With '${COMP_PRINCIPAL_BALANCE_DOLLARS}'
"
fi

Email Body Output:

Business, Finance, Occupation & Industry

The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Scler

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Sclerosis

-Data Demonstrated That DAC HYP Significantly Reduced Annualized Relapse Rate by up to 54 Percent at One Year-

-Phase 3 Study Underway to Further Assess Once-Monthly DAC HYP for Multiple Sclerosis-

WESTON, Mass.–(BUSINESS WIRE)– Today Biogen Idec (NAS: BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article in The Lancet. SELECT was a Phase 2b study designed to determine the efficacy and safety of DAC HYP in patients with relapsing-remitting multiple sclerosis (RRMS).

Published results demonstrate that both 150 mg and 300 mg subcutaneous injections of DAC HYP, administered once every four weeks, met the study’s primary endpoint by significantly reducing annualized relapse rate (ARR) by 54 percent (p<0.0001) and 50 percent (p=0.0002), respectively, compared to placebo at one year. In addition, results demonstrated that DAC HYP reduced multiple sclerosis (MS) brain lesions compared to placebo.

“DAC HYP represents the type of innovative research we are focused on cultivating as part of our MS pipeline because it potentially targets the disease in a new way,” said Gilmore O’Neill, M.D., vice president, Medical Research at Biogen Idec. “Based on these initial data from SELECT, we believe DAC HYP would complement our robust portfolio of four approved MS products by potentially offering people with MS a new treatment alternative. We look forward to continuing to work with our partners at AbbVie to progress the DAC HYP program further.”

Both doses of DAC HYP met key secondary endpoints in the study by significantly reducing the proportion of patients who relapsed at one year, as well as MS brain lesion activity, including the cumulative number of new gadolinium-enhancing (Gd+) lesions between weeks eight and 24 and the number of new or newly enlarging T2-hyperintense lesions at one year. Both doses of DAC HYP also demonstrated a trend in improvements in quality of life (QoL) compared to placebo as measured by the Multiple Sclerosis Impact Scale (MSIS-29) physical impact score.

“Because MS is unique to each person, we need a variety of treatment options to attack the disease in different ways,” said Ralf Gold, M.D., professor/chair of the Department of Neurology at St. Josef-Hospital/Ruhr-University in Bochum, Germany, and …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multi

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Biogen Idec’s TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis

– Offers a Broad Spectrum of Patients with Relapsing Forms of MS an Effective and Convenient Treatment Option –

– Reduces Relapses and Disability Progression –

– Strengthens Biogen Idec’s Portfolio of Innovative Treatments for People Living with MS –

WESTON, Mass.–(BUSINESS WIRE)– Today Biogen Idec (NAS: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TECFIDERA™ (dimethyl fumarate), a new first-line oral treatment for people with relapsing forms of multiple sclerosis (MS). Biogen Idec will make this oral capsule available to people living with MS in the United States in the coming days.

Image of Biogen Idec‘s TECFIDERA(TM) (dimethyl fumarate) which was approved by the U.S. FDA on March 27, 2013 for relapsing multiple sclerosis. (Photo: Business Wire)

TECFIDERA has been clinically proven to significantly reduce important measures of disease activity, including relapses and development of brain lesions, as well as to slow disability progression over time, while demonstrating a favorable safety and tolerability profile.

“With the FDA approval of TECFIDERA, we will offer the MS community a treatment with strong efficacy and a favorable safety profile in the convenience of a pill – a combination we believe will have a significant positive impact on the way people live with this chronic disease,” said George A. Scangos, Ph.D., chief executive officer of Biogen Idec. “Biogen Idec is committed to delivering innovative treatments and setting new standards for the next generation of medicines. We believe TECFIDERA will raise expectations for what people living with MS can achieve with their therapy.”

The FDA approval of TECFIDERA is based on data from a robust clinical development program that included DEFINE and CONFIRM, two global Phase 3 studies that enrolled more than 2,600 patients. In the ongoing extension study, ENDORSE, some patients receiving TECFIDERA have been followed for more than four years.

In DEFINE, TECFIDERA, administered twice daily, significantly reduced the proportion of patients who relapsed by 49 percent (p<0.0001), the annualized relapse rate (ARR) by 53 percent (p<0.0001), …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

CHMP Issues Positive Opinion for TECFIDERA™ (Dimethyl Fumarate) as a First-Line Treatment for Multip

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

CHMP Issues Positive Opinion for TECFIDERA ™ (Dimethyl Fumarate) as a First-Line Treatment for Multiple Sclerosis in the European Union

-European Commission Decision Anticipated In Second Quarter of 2013-

WESTON, Mass.–(BUSINESS WIRE)– Today Biogen Idec (NAS: BIIB) announced that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) recommending a marketing authorization be granted for TECFIDERA™ (dimethyl fumarate) as a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). The CHMP, on the basis of quality, safety and efficacy data submitted by Biogen Idec, considers there to be a favorable benefit-to-risk balance for TECFIDERA.

The CHMP‘s recommendation is now referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union. The U.S. Food and Drug Administration is expected to make a decision on the marketing application for TECFIDERA in the United States in the coming days.

“With the CHMP‘s positive opinion for TECFIDERA, we are one step closer to offering the European MS community a treatment with compelling efficacy and a favorable safety profile in the convenience of a pill – a combination we believe will have a significant positive impact on the way people live with this chronic disease,” said George A. Scangos, Ph.D., chief executive officer of Biogen Idec. “Biogen Idec is committed to delivering innovative treatments and setting new standards for the next generation of medicines. We believe TECFIDERA will raise expectations for what people living with MS can achieve with their therapy.”

The CHMP opinion for TECFIDERA is based on data from a large clinical development program that included two global Phase 3 studies, DEFINE and CONFIRM, involving more than 2,600 RRMS patients, as well as an ongoing extension study in which some patients have been followed for more than four years. In DEFINE, TECFIDERA, administered twice-daily, significantly reduced the proportion of patients who relapsed by 49 percent (p<0.0001), the annualized relapse rate (ARR) by 53 percent (p<0.0001), and 12-week confirmed disability progression, as measured by the Expanded Disability Status Scale (EDSS), by 38 percent (p=0.0050) compared to placebo at two years. In CONFIRM, twice-daily TECFIDERA significantly reduced ARR by 44 percent (p<0.0001) and the proportion of patients who relapsed by 34 percent (p<0.0001) compared to placebo at two years. While not statistically significant, TECFIDERA showed a 21 percent reduction in 12-week confirmed disability progression in CONFIRM. In addition, both studies showed TECFIDERA significantly reduced lesions in the brain …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY™ (Peginterferon Beta-1a

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY™ (Peginterferon Beta-1a) Presented at AAN Meeting

– Primary and Secondary Endpoints Met After One Year, Including Reductions in Relapses and Disability Progression –

– Additional Data Demonstrate Significant Effects in Decreasing Brain Lesions –

WESTON, Mass.–(BUSINESS WIRE)– Today Biogen Idec (NAS: BIIB) announced the positive, full first-year results from its two-year pivotal Phase 3 ADVANCE study of PLEGRIDY™(peginterferon beta-1a), the company’s investigational candidate for relapsing-remitting multiple sclerosis (RRMS) dosed once every two weeks or every four weeks. These data, presented today at the American Academy of Neurology’s 65th Annual Meeting, indicate that PLEGRIDY significantly reduced multiple sclerosis (MS) disease activity, including relapses, disability progression and brain lesions, compared to placebo at one year.

“These full first-year results provide a more complete picture of PLEGRIDY and its positive effects on the reduction of relapse, disability progression and lesion development,” said Peter Calabresi, M.D., director, the Johns Hopkins Multiple Sclerosis Center. “These data suggest that, if approved, PLEGRIDY may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with MS.”

Study Results for Two-Week Dosing Arm at Year One:

Primary endpoint:

  • PLEGRIDY met the primary endpoint of reducing annualized relapse rate (ARR) at one year by 36 percent compared to placebo (p=0.0007).

Secondary endpoints:

  • PLEGRIDY reduced the proportion of patients who relapsed by 39 percent compared to placebo (p=0.0003).
  • PLEGRIDY reduced the number of new or newly enlarging T2-hyperintense lesions on brain MRI scans by 67 percent compared to placebo (p<0.0001).
  • PLEGRIDY also demonstrated significant positive effects on disability progression by reducing the risk of 12-week confirmed disability progression, as measured by the Expanded Disability Status Scale (EDSS), …read more
    Source: FULL ARTICLE at DailyFinance
Business, Finance, Occupation & Industry

Walgreens Discusses Success of Community Pharmacy Programs in Improving Patient Medication Adherence

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Walgreens Discusses Success of Community Pharmacy Programs in Improving Patient Medication Adherence

Company presents research findings at World Congress Summit

DEERFIELD, Ill.–(BUSINESS WIRE)– Walgreens (NYS: WAG) (NAS: WAG) recently presented the latest research on how community pharmacy programs, as well as new adherence models and metrics, can help drive better medication adherence. The research, presented at the World Congress Summit in Philadelphia last Friday, demonstrates the company’s success in improving patient medication adherence by developing an infrastructure that tracks patient level adherence and uses predictive modeling along with risk stratification to identify patient patterns.

Kristi Rudkin, PharmD, senior director of product development for Walgreens, and Michael S. Taitel, PhD, Walgreens senior director of clinical outcomes and analytic services, discussed the research findings along with product-specific interventions focused on empowering patients to better self-manage their condition. The discussion also examined the latest research related to new-to-therapy counseling and automated Interactive Voice Responses (IVR) refill reminders.

“Medication non-adherence is one of the greatest and most costly barriers in treating illness today,” Rudkin said. “By developing programs and services that can help reduce these barriers, and examining ways to drive cost savings and improved health outcomes through better adherence, we can help more people get, stay and live well.”

New-to-therapy patients often face adherence challenges while trying to learn a new medication regimen. A retrospective cohort study assessing the impact of pharmacist-led, face-to-face counseling in new-to-therapy statin patients found that compared to usual pharmacy care, those patients receiving face-to-face counseling had 7.2 percent higher adherence.1

Forgetfulness can also be a contributor to non-adherence. In a pilot program, automated refill reminders (ARR) significantly improved patient adherence to medications used to treat chronic conditions. Patients who received automated Interactive Voice Responses (IVR) telephonic reminders had a significantly higher medication possession ratio (MPR) compared with patients who did not receive reminders. Additionally, the persistence for the intervention was nearly eight days longer than that of the control group.

“Helping patients improve their medication adherence is a challenge for providers, payers and many others within the health care system,” Taitel said. “We’ve demonstrated the effectiveness of several programs and initiatives – including our new to therapy program, automated refill reminder calls. Integrating predictive modeling and risk stratification will help us be even more effective at driving better adherence, and ultimately better health outcomes.”

…read more
Source: FULL ARTICLE at DailyFinance